Marchesi Alessandra, Recupero Rosanna, Sardella Letizia, Babini Riccardo, Gargiullo Livia, Tarissi de Jacobis Isabella, Cotugno Nicola, Bozzola Elena, Marchili Maria Rosaria, De Benedetti Fabrizio, Villani Alberto
Department of General Pediatrics and II Level Emergency, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Department of Pediatrics, A.O.U. San Giovanni di Dio e Ruggi D'Aragona, Salerno, Italy.
Front Pediatr. 2025 Aug 28;13:1636339. doi: 10.3389/fped.2025.1636339. eCollection 2025.
The incidence of coronary artery aneurysms in Kawasaki disease has been increasing for reasons that remain unclear. Recently the use of corticosteroids in KD has been reconsidered for high-risk patients. To evaluate their effectiveness as first line therapy in combination with IVIG and aspirin for selected KD patients, we performed this retrospective single-center study.
We retrospectively analyzed KD patients (aged 30 days to 18 years) who were hospitalized at the Bambino Gesù Children's Hospital between December 2007 and February 2023. The patients were classified as "high risk (HR)" or "low risk (LR)" for IVIG resistance and/or developing CAA according to the Italian guidelines and were stratified by treatment. We also analyzed changes in AHA risk class in the HR-S and HR-NS groups. Furthermore, to obtain a single representative Z-score for each patient, we introduced a novel calculation method: a. Z-MAX: the maximum value of the scores between the three coronary arteries. b. Z-SUM: the sum of the single Z-scores of the three coronary arteries.
374 patients were enrolled, 78 with CAA and 296 without CAA. Of those, 195 patients were classified as HR and all subsequent analyses in this study were exclusively conducted on this subgroup. At the end of the eight weeks, the HR-S group showed a significant reduction in coronary artery dimensions expressed as Z-score (reduction of 65% in RCA, 63% in LMCA, and 36.5% in LAD). In contrast, the HR- NS group showed an increase in the dimension of two arteries (RCA increased by 17% and LAD increased by 15%) and a slight reduction of LMCA (7.5%).
First-line therapy with IVIG plus steroids in HR-KD patients reduces the development of CAA.
川崎病冠状动脉瘤的发病率一直在上升,原因尚不清楚。最近,对于高危患者,在川崎病中使用皮质类固醇的问题已被重新审视。为了评估其作为一线治疗与静脉注射免疫球蛋白(IVIG)和阿司匹林联合用于特定川崎病患者的有效性,我们进行了这项回顾性单中心研究。
我们回顾性分析了2007年12月至2023年2月期间在 Bambino Gesù儿童医院住院的川崎病患者(年龄30天至18岁)。根据意大利指南,将患者分为静脉注射免疫球蛋白抵抗和/或发生冠状动脉瘤的“高危(HR)”或“低危(LR)”,并按治疗分层。我们还分析了HR-S组和HR-NS组中美国心脏协会(AHA)风险等级的变化。此外,为了为每位患者获得一个单一的代表性Z评分,我们引入了一种新的计算方法:a. Z-MAX:三条冠状动脉之间分数的最大值。b. Z-SUM:三条冠状动脉单个Z评分的总和。
共纳入374例患者,其中78例有冠状动脉瘤,296例无冠状动脉瘤。其中,195例患者被归类为高危,本研究所有后续分析均仅针对该亚组进行。在八周结束时,HR-S组冠状动脉尺寸以Z评分表示显著降低(右冠状动脉降低65%,左主干冠状动脉降低63%,左前降支冠状动脉降低36.5%)。相比之下,HR-NS组两条动脉尺寸增加(右冠状动脉增加17%,左前降支冠状动脉增加15%),左主干冠状动脉略有降低(7.5%)。
高危川崎病患者采用静脉注射免疫球蛋白加类固醇的一线治疗可减少冠状动脉瘤的发生。